Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
4th January 2021 | Jonathan Young | 2,960 | Open or private sale | $25.27 | $74,799.20 |
4th January 2021 | Jonathan Young | 100 | Open or private sale | $26.00 | $2,600.00 |
28th December 2020 | Andrew Cheng | 7,480 | Exercise of derivative | $0.62 | $4,637.60 |
21st December 2020 | Andrew Cheng | 10,500 | Exercise of derivative | $0.62 | $6,510.00 |
15th December 2020 | Andrew Cheng | 2,500 | Bona fide gift | $0.00 | |
11th December 2020 | Andrew Cheng | 50 | Bona fide gift | $0.00 | |
24th November 2020 | Tree Partners Iv, L.P. Apple | 375,000 | Open or private purchase | $39.00 | $14,625,000.00 |
24th November 2020 | Seth Loring Harrison | 375,000 | Open or private purchase | $39.00 | $14,625,000.00 |
23rd November 2020 | G. Walmsley Graham | 1,183,114 | Conversion of derivative | $0.00 | |
23rd November 2020 | G. Walmsley Graham | 1,400,761 | Conversion of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 8/10.
Akero Therapeutics, Inc. operates as a biotechnology company. The firm specializes in transformational treatments for non-alcoholic steatohepatitis (NASH) and other serious metabolic diseases.
6th November 2020
6th November 2020
6th November 2020